Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mediocre Q4 sales for Thoratec's HeartMate LVAD

This article was originally published in Clinica

Executive Summary

Thoratec ended last week on a negative note as its share price fell 8% to close at $9.83 on Friday (December 3), the day after the company forecast flat fourth-quarter sales of its HeartMate XVE left ventricular assist device (LVAD). Implant rates of the product for the first two months of the fourth quarter have been similar to those of the previous quarters in 2004, which ranged between 34 and 42 implants per quarter, according to Thoratec.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT060403

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel